Media Summary: In this webinar, Dr. Lai will discuss the latest research presented at the Speakers: Uma Borate, Andrew M. Brunner, Amer Zeidan. Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, shares his enthusiasm for advances in the field of ...

2023 Eha Asco Updates Mds And Aml - Detailed Analysis & Overview

In this webinar, Dr. Lai will discuss the latest research presented at the Speakers: Uma Borate, Andrew M. Brunner, Amer Zeidan. Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, shares his enthusiasm for advances in the field of ... Learn about upcoming treatments and current research breakthroughs for patients with In this webinar, Dr. Andrew Brunner will present the most promising research presented at the 2021 European Hematology ... Shai Shimony , MD, Dana-Farber Cancer Institute, Boston, MA, shares some key

Dr Esther Oliva reviews the latest key data on new and emerging treatments for patients with higher-risk Richard Stone, MD, Dana-Farber Cancer Institute, Boston, MA, outlines the key differences between the International Consensus ... In this webinar, Dr. Lourdes Mendez discusses research most relevant to patients reported over the past year on the biology and ... Pramila Krishnamurthy, MA, FRCPath, MRCP, PhD, King's College Hospital NHS Foundation Trust, London, UK, discusses ... In this video, Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, gives an overview of what to look ... Oncology Today with Dr Neil Love: Key Presentations from the 2025

Blood Cancers Today Associate Elias Jabbour, MD, gives an David Sallman, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, reviews the toleratbility and efficacy data ... Nicholas Short, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the rationale and preliminary ... Interview with David Swoboda, MD from Tampa General Hospital & Cancer Center of South Florida at Yishai Ofran, MD, Rambam Health Care Campus, Haifa, Israel, discusses the approach needed to treat patients with

Photo Gallery

2023 EHA/ASCO Updates: MDS and AML
Post ASCO/EHA 2023 Roundtable Discussion on the latest updates in MDS
Top highlights from ASCO & EHA 2023
Updates from ASCO and EHA Meeting 2022 about MDS Research and Treatments
Updates from EHA and ASCO 2021
ASCO 2023: Updates on Use of ESAs in Low-Risk MDS highlighting COMMANDS Clinical Trial
Highlights in AML and MDS from EHA 2022
Higher-risk MDS and newly diagnosed AML: What are the latest developments from EHA 2022?
Updates in the diagnosis, risk stratification & treatment of AML: WHO, ICC, and ELN classifications
Updates from ASH22 on MDS and AML, featuring Lourdes Mendez, MD
Approaching patients with MDS and AML who relapse after alloSCT & strategies to prevent relapse
ASCO/EHA 2023 Special: Updates on CAR T-cell Therapy in Myeloma
View Detailed Profile
2023 EHA/ASCO Updates: MDS and AML

2023 EHA/ASCO Updates: MDS and AML

In this webinar, Dr. Lai will discuss the latest research presented at the

Post ASCO/EHA 2023 Roundtable Discussion on the latest updates in MDS

Post ASCO/EHA 2023 Roundtable Discussion on the latest updates in MDS

Speakers: Uma Borate, Andrew M. Brunner, Amer Zeidan.

Top highlights from ASCO & EHA 2023

Top highlights from ASCO & EHA 2023

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, shares his enthusiasm for advances in the field of ...

Updates from ASCO and EHA Meeting 2022 about MDS Research and Treatments

Updates from ASCO and EHA Meeting 2022 about MDS Research and Treatments

Learn about upcoming treatments and current research breakthroughs for patients with

Updates from EHA and ASCO 2021

Updates from EHA and ASCO 2021

In this webinar, Dr. Andrew Brunner will present the most promising research presented at the 2021 European Hematology ...

ASCO 2023: Updates on Use of ESAs in Low-Risk MDS highlighting COMMANDS Clinical Trial

ASCO 2023: Updates on Use of ESAs in Low-Risk MDS highlighting COMMANDS Clinical Trial

ASCO 2023

Highlights in AML and MDS from EHA 2022

Highlights in AML and MDS from EHA 2022

Shai Shimony , MD, Dana-Farber Cancer Institute, Boston, MA, shares some key

Higher-risk MDS and newly diagnosed AML: What are the latest developments from EHA 2022?

Higher-risk MDS and newly diagnosed AML: What are the latest developments from EHA 2022?

Dr Esther Oliva reviews the latest key data on new and emerging treatments for patients with higher-risk

Updates in the diagnosis, risk stratification & treatment of AML: WHO, ICC, and ELN classifications

Updates in the diagnosis, risk stratification & treatment of AML: WHO, ICC, and ELN classifications

Richard Stone, MD, Dana-Farber Cancer Institute, Boston, MA, outlines the key differences between the International Consensus ...

Updates from ASH22 on MDS and AML, featuring Lourdes Mendez, MD

Updates from ASH22 on MDS and AML, featuring Lourdes Mendez, MD

In this webinar, Dr. Lourdes Mendez discusses research most relevant to patients reported over the past year on the biology and ...

Approaching patients with MDS and AML who relapse after alloSCT & strategies to prevent relapse

Approaching patients with MDS and AML who relapse after alloSCT & strategies to prevent relapse

Pramila Krishnamurthy, MA, FRCPath, MRCP, PhD, King's College Hospital NHS Foundation Trust, London, UK, discusses ...

ASCO/EHA 2023 Special: Updates on CAR T-cell Therapy in Myeloma

ASCO/EHA 2023 Special: Updates on CAR T-cell Therapy in Myeloma

In this episode, we discuss the latest

Looking forward to EHA 2023: CARTITUDE-4, bispecifics, novel combinations and more

Looking forward to EHA 2023: CARTITUDE-4, bispecifics, novel combinations and more

In this video, Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, gives an overview of what to look ...

Key Presentations from the 2025 ASCO Meeting and the EHA 2025 Congress — Acute Myeloid Leukemia

Key Presentations from the 2025 ASCO Meeting and the EHA 2025 Congress — Acute Myeloid Leukemia

Oncology Today with Dr Neil Love: Key Presentations from the 2025

2023 EHA Leukemia Update from Elias Jabbour, MD

2023 EHA Leukemia Update from Elias Jabbour, MD

Blood Cancers Today Associate Elias Jabbour, MD, gives an

Magrolimab + azacitidine in MDS and AML

Magrolimab + azacitidine in MDS and AML

David Sallman, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, reviews the toleratbility and efficacy data ...

Mid-Year Updates in AML Research | Dr. Daver EHA 2022 with Q&A #AML

Mid-Year Updates in AML Research | Dr. Daver EHA 2022 with Q&A #AML

This HealthTree Round Table for

Pevonedistat, azacitidine and venetoclax triplet therapy for AML, MDS and CMML

Pevonedistat, azacitidine and venetoclax triplet therapy for AML, MDS and CMML

Nicholas Short, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the rationale and preliminary ...

Advancements in AML & MDS: Genetic Sequencing & Immune Therapies | David Swoboda, MD | ASCO 2023

Advancements in AML & MDS: Genetic Sequencing & Immune Therapies | David Swoboda, MD | ASCO 2023

Interview with David Swoboda, MD from Tampa General Hospital & Cancer Center of South Florida at

MDS, inflammation and AML

MDS, inflammation and AML

Yishai Ofran, MD, Rambam Health Care Campus, Haifa, Israel, discusses the approach needed to treat patients with